Apreo Health Secures $130M to Propel BREATHE Implant Toward Pivotal Emphysema Trial

California, August 7, 2025 (Yahoofinance)  --  California-based startup Apreo Health has secured $130 million in a Series B funding round co-led by Bain Capital Life Sciences and Norwest, bringing the company’s total funding to approximately $153 million. The financing will support the initiation of the pivotal BREATHE-3 trial for Apreo’s BREATHE Airway Scaffold, an implant designed to relieve lung hyperinflation in patients with severe emphysema, while also advancing regulatory activities and early commercialization efforts. The BREATHE implant, delivered bronchoscopically, has received FDA breakthrough device designation and is currently being evaluated in the ongoing Phase II BREATHE-2 trial.

Read full article here.